Company / R&D Expense
ABEONA THERAPEUTICS INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$26.8M
FY2025
5-year range
$26.8M / $38.7M
FY2021-FY2025
Trend
-13.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $5M in FY2016 to $49M in FY2020.
Based on SEC 10-K filings.
$27M in FY2025 with a 5-year CAGR of -11.2%.
Declined from $29M to $27M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -11.5%
- 5-Year CAGR
- -11.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -11.2%, indicating a declining trend.
- In FY2025, r&d expense decreased 13.8% year-over-year.
- Peak r&d expense was recorded in FY2020.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.42 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.8M | -13.8% |
| FY2024 | $31.1M | +7.3% |
| FY2023 | $29.0M | -25.2% |
| FY2022 | $38.7M | +28.5% |
| FY2021 | $30.1M | -37.9% |
| FY2020 | $48.6M | +185.9% |
| FY2019 | $17.0M | -56.1% |
| FY2018 | $38.7M | +127.8% |
| FY2017 | $17.0M | +260.3% |
| FY2016 | $4.7M | +1315.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026